Concord Biotech To Hold Q1 Earnings Call On August 3 At 3:30 PM
NiveshIQ
NSE: CONCORDBIO · IT
Concord Biotech Ltd.
₹1,330.40▲ ₹74.30 (+5.92%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on CONCORDBIO. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Concord Biotech Ltd.
Concord Biotech Limited is a biopharma company engaged in research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides a range of products across immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. Key products include tacrolimus, mycophenolate mofetil, mycophenolate sodium, and temsirolimus, among others. Despite a 12% decline in revenue in FY 2026, the company expects strong growth and margin improvement in FY 2027. Concord Biotech has a diversified product portfolio and a strategic acquisition in place, positioning it for future growth. The company has also declared a dividend of ₹7.55 for the financial year ended March 31, 2026. With a solid growth track record and a strong produ
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,017 Cr +19.20% | ₹1,200 Cr +18.00% | ₹1,055 Cr -12.10% |
| EBITDA Margin | 41.89% | 41.83% | 39.79% |
| Net Profit | ₹308.00 Cr +28.30% | ₹372.00 Cr +20.80% | ₹259.23 Cr -30.30% |
| EPS | ₹29.45 | ₹35.52 | ₹24.78 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Concord Biotech Q1 Results: Earnings Call Scheduled for Aug 3 to Discuss Q1FY27 Performance
Concord Biotech Ltd. Yearly results, Financial Summary
🔒
+ 3 more stories about Concord Biotech Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹326 Cr, PAT ₹88 Cr, EPS ₹8.46, EBITDA margin 41.1%. Growth context: revenue YoY +9.5%, PAT YoY +0.9%, revenue QoQ +17.3%, PAT QoQ +38.2%. Street verdict: strong miss, revenue surprise -11.9%, PAT surprise -18.7%.
Management commentary points to product launches, approvals, and therapy-mix improvement and new product launches and ma...
FY26 (last completed FY): revenue ₹1, 055 Cr, PAT ₹259 Cr, EBITDA margin 39.8%, EPS ₹24.78. Year-on-year: revenue YoY -1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for CONCORDBIO
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track CONCORDBIO alongside your other holdings
Unlock full CONCORDBIO research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Concord Biotech Ltd.?
NiveshIQ detects active intelligence signals for Concord Biotech Ltd. (CONCORDBIO) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Concord Biotech Ltd.?
Concord Biotech Ltd. operates in the IT sector with a market capitalisation of ₹1,224,009.6L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.